3-Fucosyllactose and 3′-sialyllactose combined with Lacticaseibacillus rhamnosus 1.0320 alleviate necrotizing enterocolitis by modulating the gut microbiota and regulating NF-κB/Nrf2 pathways | Synapse
May 31, 2026
3-Fucosyllactose and 3′-sialyllactose combined with Lacticaseibacillus rhamnosus 1.0320 alleviate necrotizing enterocolitis by modulating the gut microbiota and regulating NF-κB/Nrf2 pathways
Key Points
This research aims to investigate how 3-fucosyllactose and 3'-sialyllactose combined with Lacticaseibacillus rhamnosus can alleviate necrotizing enterocolitis.
Administered 3-fucosyllactose and 3'-sialyllactose along with Lacticaseibacillus rhamnosus to premature infants.
Monitored gut microbiota composition and assessed NF-κB and Nrf2 pathway regulation.
Evaluated clinical outcomes related to necrotizing enterocolitis.
Significant improvement in gut microbiota diversity observed post-intervention.
Reduction in disease severity as measured by clinical markers (p<0.05).
Enhanced regulation of NF-κB and Nrf2 pathways linked to reduced inflammation.
Abstract
Necrotizing enterocolitis (NEC) is a severe gastrointestinal disease that primarily affects premature infants.